PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29321374-3	2018	Here, we show that a potentially novel anti-CD28 domain antibody (dAb) that selectively blocks CD28 but preserves CTLA-4 coinhibition confers improved allograft survival in sensitized recipients as compared with CTLA-4 Ig.	3,3'-Diaminobenzidine	66-69	CD28 molecule	Homo sapiens	44-48	
32203908-2	2020	We found that selective CD28 blockade with a domain antibody (dAb) inhibited Th1 cells but surprisingly augmented Th17 responses.	3,3'-Diaminobenzidine	62-65	CD28 molecule	Homo sapiens	24-28	
30801917-2	2019	Recently, anti-CD28 domain antibodies (dAb) that selectively target CD28 while leaving CTLA-4 intact were shown to more effectively inhibit alloimmune responses and prolong graft survival.	3,3'-Diaminobenzidine	39-42	CD28 molecule	Homo sapiens	15-19	
30801917-2	2019	Recently, anti-CD28 domain antibodies (dAb) that selectively target CD28 while leaving CTLA-4 intact were shown to more effectively inhibit alloimmune responses and prolong graft survival.	3,3'-Diaminobenzidine	39-42	CD28 molecule	Homo sapiens	68-72	
29321374-3	2018	Here, we show that a potentially novel anti-CD28 domain antibody (dAb) that selectively blocks CD28 but preserves CTLA-4 coinhibition confers improved allograft survival in sensitized recipients as compared with CTLA-4 Ig.	3,3'-Diaminobenzidine	66-69	CD28 molecule	Homo sapiens	95-99	
29321374-4	2018	However, both CTLA-4 Ig and anti-CD28 dAb similarly and significantly reduced the accumulation of donor-reactive CD8+ memory T cells, demonstrating that regulation of the expansion of CD8+ memory T cell populations is controlled in part by CD28 signals and is not significantly impacted by CTLA-4.	3,3'-Diaminobenzidine	38-41	CD28 molecule	Homo sapiens	33-37	
29321374-4	2018	However, both CTLA-4 Ig and anti-CD28 dAb similarly and significantly reduced the accumulation of donor-reactive CD8+ memory T cells, demonstrating that regulation of the expansion of CD8+ memory T cell populations is controlled in part by CD28 signals and is not significantly impacted by CTLA-4.	3,3'-Diaminobenzidine	38-41	CD28 molecule	Homo sapiens	240-244	
28637095-6	2018	We observed that the anti-CD28 dAb led to superior inhibition of donor-reactive CXCR5+ PD-1high Tfh cells, CD95+ GL7+ germinal center B cells and DSA formation compared with CTLA4-Ig.	3,3'-Diaminobenzidine	31-34	CD28 molecule	Homo sapiens	26-30	
28637095-7	2018	Interestingly, donor-reactive Tfh cells differentially upregulated CTLA4 expression, suggesting an important role for CTLA4 in mediating the superior inhibition observed with the anti-CD28 dAb.	3,3'-Diaminobenzidine	189-192	CD28 molecule	Homo sapiens	184-188	
24081989-6	2013	The anti-CD28 dAb is equipotent in the inhibition of CD80- and CD86-mediated T cell proliferation and does not interfere with CTLA-4-mediated downmodulation of CD86 expression on APCs.	3,3'-Diaminobenzidine	14-17	CD28 molecule	Homo sapiens	9-13	
24081989-8	2013	In cynomolgus monkeys, the anti-CD28 dAb demonstrated pharmacodynamic activity, as measured by the inhibition of a T cell-dependent Ab response, without evidence of T cell depletion or cytokine release.	3,3'-Diaminobenzidine	37-40	CD28 molecule	Homo sapiens	32-36	
24081989-10	2013	Taken together, these data support clinical evaluation of this novel anti-CD28 dAb for the treatment of autoimmune diseases.	3,3'-Diaminobenzidine	79-82	CD28 molecule	Homo sapiens	74-78	
26442523-1	2015	BMS-931699 (lulizumab pegol), a domain antibody (dAb) conjugated with 40-kDa branched polyethylene glycol, is a human anti-CD28 receptor antagonist under development for the treatment of inflammatory and autoimmune diseases.	3,3'-Diaminobenzidine	49-52	CD28 molecule	Homo sapiens	123-127